Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - H.C. Wainwright raised its price target on EMX Royalty Corporation (NYSE:EMX) to $5.75 from $5.00 on Wednesday, while maintaining a Buy rating on the stock. The $341 million market cap company has shown impressive momentum, with shares surging over 81% year-to-date. According to InvestingPro data, EMX maintains a strong financial health rating.
The royalty company reported total revenue of $6.2 million in the second quarter, resulting in net income of $0.6 million, or $0.01 per share. These results showed improvement compared to the second quarter of 2024, which saw revenue of $6.0 million and a net loss of $4.0 million, or ($0.04) per share. The company maintains a healthy gross profit margin of 64.4% and an impressive current ratio of 8.56, indicating strong liquidity.
EMX received early property payments of approximately $8.4 million from AbraSilver and Aftermath, which boosted its adjusted operating cash flows to $9.0 million, up from $1.3 million in the same quarter last year.
The company utilized its strong cash position to repay $10.0 million of its credit facility with Franco-Nevada and repurchased 1.2 million common shares worth $2.6 million through its share repurchase program.
H.C. Wainwright expects EMX to continue expanding its royalty portfolio while focusing on ongoing cost reduction initiatives, supporting the firm’s decision to raise its price target. InvestingPro analysis reveals 15 additional investment tips for EMX, including insights on management’s aggressive share buyback strategy and future growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.